Effect on triglyceride levels (primary endpoint)
Pegozafermin substantially reduced
Pegozafermin substantially reduced TGs after 8 weeks of therapy across all dose groups, with placebo-corrected changes from baseline ranging from −29.0% to −52.9%. Pooled pegozafermin data showed a placebo-corrected median percent change in TG levels of −43.7% (−57.3% versus −11.9% placebo; 95% confidence interval (CI): −57.1%, −30.3%; 